Reaktion #2033053

ord-80292d58373c41dfb2dfeb843c4c2d86

Reaktionsgleichung

Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(CBr)n(C)c2n1
4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine
CC(C)(N)c1ccccc1
2-phenylpropan-2-amine
→
Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(CNC(C)(C)c3ccccc3)n(C)c2n1
N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)-2-phenylpropan-2-amine

Edukte

Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(CBr)n(C)c2n1
4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine
CC(C)(N)c1ccccc1
2-phenylpropan-2-amine

Reagenzien

Keine

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    Sonstigeto give
  2. 2
    Sonstige7.4 mg of 303 following reverse phase purification

Vorschrift

4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with 2-phenylpropan-2-amine via General Procedure E to give 7.4 mg of 303 following reverse phase purification. MS (Q1) 497.2 (M)+

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08394796B2uspto-grants-2013_03